Some Issues of Sample Size Calculation for Time-to-Event Endpoints Using the Freedman and Schoenfeld Formulas.

Abstract:

:This article deals with seven special issues related to the assumptions, applicability, and practical use of formulas for calculating power or sample size, respectively, for comparative clinical trials with time-to-event endpoints, with particular focus on the well-known Freedman and Schoenfeld methods. All problems addressed are illustrated by numerical examples, and recommendations are given on how to deal with them in the planning of clinical trials.

journal_name

J Biopharm Stat

authors

Abel UR,Jensen K,Karapanagiotou-Schenkel I,Kieser M

doi

10.1080/10543406.2014.1000546

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

1285-311

issue

6

eissn

1054-3406

issn

1520-5711

journal_volume

25

pub_type

杂志文章
  • A global model to define the behavior of partial agonists (bell-shaped dose-response inducers) in pharmacological evaluation of activity in the presence of the full agonist.

    abstract::The dose-response models for full agonists and for a particular type of partial agonist can be described by sigmoidal curves and bell-shaped curves, respectively. The methods currently used to evaluate the interaction of a full agonist and a partial agonist require a large number of experimental units and base their a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409808835266

    authors: Ghosh K,Shen ES,Arey BJ,López FJ

    更新日期:1998-11-01 00:00:00

  • Identification of Risk Factors and Likelihood of Benefit from Adjuvant Chemotherapy for Early Stage Lung Cancer Patients.

    abstract::The purpose of the research is to develop a statistical decision support algorithm for patients who may benefit from Adjuvant Cisplatin/Vinorelbine (ACT) and improve their survival rates. Genome-wide microarray data are used to identify feasible sets of genes and probe sets that constitute the gene signature. The data...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2019.1684310

    authors: Moon H,Chao T,Ahn H

    更新日期:2020-05-03 00:00:00

  • Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.

    abstract::The design of a three-arm trial including the experimental treatment, an active reference treatment, and a placebo is recommended as a useful approach to the assessment of noninferiority of the experimental treatment. The inclusion of the placebo arm enables the assessment of assay sensitivity and internal validation,...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2013.789893

    authors: Hida E,Tango T

    更新日期:2013-01-01 00:00:00

  • Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses.

    abstract::It has been widely recognized that interim analyses of accumulating data in a clinical trial can inflate type I error. Different methods, from group sequential boundaries to flexible alpha spending functions, have been developed to control the overall type I error at prespecified level. These methods mainly apply to t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.901341

    authors: Chen LM,Ibrahim JG,Chu H

    更新日期:2014-01-01 00:00:00

  • Statistical Properties of the Design for Simultaneous Global Drug Development Program.

    abstract::Recently, a design was proposed for the Simultaneous Global Drug Development Program (SGDDP) to assess the impact of ethnic factors on the effect of a new treatment for a targeted ethnic (TE) population. It used weighted Z tests to combine the information collected from the TE and non-TE (NTE) subgroups in the SGDDP b...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.971166

    authors: Liu K,Yuan Z,Chen G,Huang Q,Wenrich J

    更新日期:2015-01-01 00:00:00

  • On the establishment of equivalence acceptance criterion in analytical similarity assessment.

    abstract::For the assessment of biosimilarity of biosimilar products, the United States (US) Food and Drug Administration (FDA) proposed a stepwise approach for providing the totality-of-the-evidence of similarity between a proposed biosimilar product and a US-licensed (reference) product. The stepwise approach starts with the ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2016.1265539

    authors: Wang T,Chow SC

    更新日期:2017-01-01 00:00:00

  • An equivalence test for the comparison between a test drug and placebo in human abuse potential studies.

    abstract::Statistical methodologies for human abuse potential studies are rarely evaluated. Human abuse potential studies assess whether test drugs produce positive and negative subjective responses on abuse-related measures using volunteers with histories of recreational drug use. These studies typically have a randomized, dou...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2011.616972

    authors: Chen L,Bonson KR

    更新日期:2013-03-11 00:00:00

  • An evaluation of increasing sample size based on conditional power.

    abstract::We evaluate properties of sample size re-estimation (SSR) designs similar to the promising zone design considered by Mehta and Pocock (2011). We evaluate these designs under the assumption of a true effect size of 1.1 down to 0.4 of the protocol-specified effect size by six measures: 1. The probability of a sample siz...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1289943

    authors: Gaffney M,Ware JH

    更新日期:2017-01-01 00:00:00

  • Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database.

    abstract::In 1968 the Food and Drug Administration (FDA) established the Adverse Event Reporting System (AERS) database containing data on adverse events (AEs) reported by patients, health care providers, and other sources through a spontaneous reporting system. FDA uses AERS for monitoring the safety of the drugs on the market...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2013.736810

    authors: Huang L,Zalkikar J,Tiwari RC

    更新日期:2013-01-01 00:00:00

  • Assessment of selection bias in estimates of relative bioavailability and intrasubject variability from bioequivalence evaluations.

    abstract::The outcome selection of bioequivalence evaluations for abbreviated new drug applications results in bias towards unity of test-reference ratio estimates, and underestimation of intrasubject variability for the test drug product. In this study, the selection bias in the estimates of testreference ratio and intrasubjec...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-100102503

    authors: Wang Y

    更新日期:2000-08-01 00:00:00

  • False-positive error rates in routine application of repeated measurements ANOVA.

    abstract::Failure to recognize the serious implications of heterogeneous correlations and disregard of the multiple test problem in interpreting the results from repeated measurements ANOVA of any single primary outcome measure can produce false-positive error rates that are more than five times the alpha level that is reported...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409608835123

    authors: Overall JE,Doyle SR

    更新日期:1996-03-01 00:00:00

  • Mixture-based gatekeeping procedures in adaptive clinical trials.

    abstract::Clinical trials with data-driven decision rules often pursue multiple clinical objectives such as the evaluation of several endpoints or several doses of an experimental treatment. These complex analysis strategies give rise to "multivariate" multiplicity problems with several components or sources of multiplicity. A ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1399901

    authors: Kordzakhia G,Dmitrienko A,Ishida E

    更新日期:2018-01-01 00:00:00

  • A bias correction in testing treatment efficacy under informative dropout in clinical trials.

    abstract::In clinical trials of drug development, patients are often followed for a certain period of time, and the outcome variables are measured at scheduled time intervals. The main interest of the trial is the treatment efficacy at a prespecified time point, which is often the last visit. In such trials, patient dropout is ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400903242753

    authors: Kong F,Chen YF,Jin K

    更新日期:2009-11-01 00:00:00

  • Ratio of means vs. difference of means as measures of superiority, noninferiority, and average bioequivalence.

    abstract::Ratio of means (ROM) and difference of means (DOM) are often used in a superiority, noninferiority (NI), or average bioequivalence (ABE) test to evaluate whether the test mean is superior, NI, or equivalent to the reference (placebo or active control) mean. The literature provides recommendations regarding how to choo...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2016.1265536

    authors: Sun W,Grosser S,Tsong Y

    更新日期:2017-01-01 00:00:00

  • On Enrichment Strategies for Biomarker Stratified Clinical Trials.

    abstract::In the era of precision medicine, drugs are increasingly developed to target subgroups of patients with certain biomarkers. In large all-comer trials using a biomarker stratified design, the cost of treating and following patients for clinical outcomes may be prohibitive. With a fixed number of randomized patients, th...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1379532

    authors: Wang X,Zhou J,Wang T,George SL

    更新日期:2018-01-01 00:00:00

  • On identifying effective and superior drug combinations via Holm's procedure based on the min tests.

    abstract::In this paper I consider a problem of identifying all effective and superior drug combinations. I formulate this problem in terms of a family of hypotheses and propose a two-stage method to solve it. The first stage uses individual p-values obtained via the Min tests, whereas Holm's approach is employed in the second ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400802622469

    authors: Soulakova JN

    更新日期:2009-01-01 00:00:00

  • Design and sample size for evaluating combinations of drugs of linear and loglinear dose-response curves.

    abstract::The study of drug combinations has become important in drug development due to its potential for efficacy at lower, less toxic doses and the need to move new therapies rapidly into clinical trials. The goal is to identify which combinations are additive, synergistic, or antagonistic. Although there exists statistical ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400902964019

    authors: Fang HB,Tian GL,Li W,Tan M

    更新日期:2009-07-01 00:00:00

  • Multivariate nonparametric analysis for the two-period crossover design with application in clinical trials.

    abstract::Nonparametric methods are presented for the analysis of the two-treatment, two-period crossover design with multivariate response. After forming within-subject sums and differences, the usual tests, including those for carry-over effects and direct treatment effects, can be constructed using a multivariate analysis of...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409308835045

    authors: Johnson WD,Grender JM

    更新日期:1993-03-01 00:00:00

  • FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.

    abstract::The Food and Drug Administration of the United States issued a draft guidance on adaptive design clinical trials in February 2010. This draft guidance has attracted a lot of attention because of the increasing interest in adaptive trials by the pharmaceutical industry in recent years. In this paper, we report on highl...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2010.514456

    authors: Chuang-Stein C,Beltangady M

    更新日期:2010-11-01 00:00:00

  • Bayesian statistics in medical devices: innovation sparked by the FDA.

    abstract::Bayesian statistical methodology has been used for more than 10 years in medical device premarket submissions to the U.S. Food and Drug Administration (FDA). A complete list of the publicly available information associated with these FDA applications is presented. In addition to the increasing number of Bayesian metho...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2011.589638

    authors: Campbell G

    更新日期:2011-09-01 00:00:00

  • Subgroup analyses in randomized clinical trials: statistical and regulatory issues.

    abstract::Recently, two CPMP Points to Consider, one on adjustment for baseline covariates and the other on multiplicity issues in clinical trials, have included recommendations on the use of subgroup analysis for regulatory purposes. However, despite their regular use and regulatory attention, the validity and nature of subgro...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-200067988

    authors: Grouin JM,Coste M,Lewis J

    更新日期:2005-01-01 00:00:00

  • Estimating vaccine efficacy from outbreak size household data in the presence of heterogeneous transmission probabilities.

    abstract::We develop a Bayesian approach for estimating vaccine efficacy for susceptibility (VEs) and infectiousness (VEI) using outbreak size household data. Our method allows for heterogeneity in transmission probabilities due to factors that are related to individuals' characteristics, such as age, in addition to vaccination...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400600719467

    authors: Davis XM,Waller LA,Haber M

    更新日期:2006-01-01 00:00:00

  • Power and sample size for the S:T repeated measures design combined with a linear mixed-effects model allowing for missing data.

    abstract::Tango (Biostatistics 2016) proposed a new repeated measures design called the S:T repeated measures design, combined with generalized linear mixed-effects models and sample size calculations for a test of the average treatment effect that depend not only on the number of subjects but on the number of repeated measures...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2017.1293083

    authors: Tango T

    更新日期:2017-01-01 00:00:00

  • Statistical assessment of biosimilarity based on the relative distance between follow-on biologics for binary endpoints.

    abstract::A new three-arm parallel design was recently proposed to investigate the biosimilarity between a biological product and a reference product by using the relative distance. The purpose of this article is to extend their results to binary endpoints for three popular metrics: the risk difference, the log relative risk, a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2014.979195

    authors: Shin W,Kang SH

    更新日期:2016-01-01 00:00:00

  • Confidence interval of the difference between two proportions with overdispersion.

    abstract::In confidence interval estimation of the difference between two proportions with overdispersion due to positive correlations, the usual asymptotic normality-based method generally has lower coverage rates than desired, especially when sample size is moderate. Applying the concept of effective sample size to existing m...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1081/BIP-120037193

    authors: Chen C,Li J,Zhou Z

    更新日期:2004-05-01 00:00:00

  • Crossover versus parallel designs: dose-escalation design comparisons for first-in-human studies.

    abstract::We study the statistical efficiency for rising-dose designs in the context of first-in-human studies. Specifically, we identify a class of crossover designs that are appealing in terms of both subject safety and statistical efficiency and, for a three-period, two-panel design in such a class, we compare its A-efficien...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2013.792827

    authors: Yan Z,Hosmane B,Locke C

    更新日期:2013-01-01 00:00:00

  • Generalized estimating equations for multivariate response with the variates having different distributions.

    abstract::This paper addresses the problem of analyzing multivariate response with the variates having different distributions. We use the generalized estimating equations proposed by Prentice and Zhao (1) to estimate mean and covariance parameters. Wald statistics are used to test hypotheses about the parameters. Data from a t...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543409608835129

    authors: May WL,Johnson WD

    更新日期:1996-05-01 00:00:00

  • Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information.

    abstract::A common question in clinical studies is how to use historical data from earlier studies, leveraging relevant information into the design and analysis of a new study. Bayesian approaches are particularly well-suited to this task, with their natural ability to borrow strength across data sources. In this paper, we prop...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543406.2016.1226324

    authors: Li JX,Chen WC,Scott JA

    更新日期:2016-01-01 00:00:00

  • Statistical considerations in setting product specifications.

    abstract::According to ICH Q6A (1999), a specification is defined as a list of tests, references to analytical procedures, and appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for the tests described. For drug products, specifications usually consist of test methods and acceptance criteria ...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章,评审

    doi:10.1080/10543406.2014.972511

    authors: Dong X,Tsong Y,Shen M

    更新日期:2015-01-01 00:00:00

  • Conditional and unconditional confidence intervals following a group sequential test.

    abstract::After a group sequential test, the naive confidence interval (CI) is usually biased in the sense that it does not cover the true parameter at the correct nominal level. Furthermore, when the stopping time is taken into account, the actual conditional confidence coverage probability can be much less accurate. In this a...

    journal_title:Journal of biopharmaceutical statistics

    pub_type: 杂志文章

    doi:10.1080/10543400500406595

    authors: Fan X,DeMets DL

    更新日期:2006-01-01 00:00:00